MARKET

BPTH

BPTH

Bio-Path Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.840
-0.105
-2.65%
Closed 16:00 01/18 EST
OPEN
3.910
PREV CLOSE
3.945
HIGH
3.940
LOW
3.780
VOLUME
46.16K
TURNOVER
--
52 WEEK HIGH
24.34
52 WEEK LOW
3.720
MARKET CAP
27.50M
P/E (TTM)
-2.4415
1D
5D
1M
3M
1Y
5Y
40 Stocks Moving In Monday's Mid-Day Session
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.
Benzinga · 12/13/2021 18:08
Bio-Path Holdings Presents Data From Ongoing Phase 2 Study Of Prexigebersen At 2021 American Society of Hematology Annual Meeting
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today
Benzinga · 12/13/2021 12:14
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday.
Benzinga · 12/13/2021 11:45
Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 12/06/2021 09:22
BRIEF-Bio Path Holdings Reports Q3 Loss Per Share $0.29
reuters.com · 11/12/2021 12:17
Bio-Path EPS beats by $0.07
Bio-Path (NASDAQ:BPTH): Q3 GAAP EPS of -$0.29 beats by $0.07. As of September 30, 2021, the Company had cash of $26.6M, compared to $13.8M at December 31, 2020.  Press Release
Seekingalpha · 11/12/2021 12:02
Notable earnings before Friday's open
AZN, BKKT, BKSY, BPTH, CAAS, CASI, OTCQX:CCHWF, CGEN, OTCQX:DTEGF, EMAN, GP, OTCPK:HNHAF, HYZN, ITRM, MIR, MOTS, NGD, NXTD, PX, SOHO, SPB, STRR, OTCPK:TOSBF, VERO, OTCPK:VITFF, VIVO For Seeking Alpha's full
Seekingalpha · 11/11/2021 15:45
BRIEF-Bio-Path Announces Clearance Of IND Application For Phase 1/1B Clinical Trial Of Prexigebersen-A In Solid Tumors
reuters.com · 10/27/2021 12:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPTH. Analyze the recent business situations of Bio-Path Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BPTH stock price target is 12.50 with a high estimate of 13.00 and a low estimate of 12.00.
High13.00
Average12.50
Low12.00
Current 3.840
EPS
Actual
Estimate
-0.62-0.47-0.31-0.16
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 34
Institutional Holdings: 964.39K
% Owned: 13.47%
Shares Outstanding: 7.16M
TypeInstitutionsShares
Increased
4
21.81K
New
0
0
Decreased
6
29.50K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.74%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Chief Financial Officer/Treasurer/Director
Peter Nielsen
Director of Investor Relations/Secretary/Director/IR Contact Officer
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Martina Molsbergen
No Data
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.